Therapeutic Considerations for the Malignant Carcinoid Syndrome

Reference

• Feldman J M, O'Dorosio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 1986; 81: 41–8
   PubMed Web of Science ®Google Scholar
• Conlon J M, Deacon C F, Richter G, Stockmann F, Creutzfeldt W. Circulating tachykinins (Substance P, neurokinin A, neuropeptide K) and the carcinoid flush. Scand J Gastroenterol 1987; 22: 97–105
   PubMed Web of Science ®Google Scholar
• Norheim I, Theodorsson-Norheim E, öberg K. Tachykinins are a new family of peptides important for the diagnosis and treatment of carcinoids. Lakartidningen 1987; 84: 630–2
   PubMedGoogle Scholar
• Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1983; 1: 727
   PubMed Web of Science ®Google Scholar
• Anderson J V, Coupe M O, Morris J A, Hodgson H JF, Bloom SR. Remission of symptoms in carcinoid syndrome with a new 5-hydroxytryptamine M receptor antagonist. Br Med J 1987; 294: 1129
   PubMed Web of Science ®Google Scholar
• Moertel CG. Clinical management of advanced gastrointestinal cancer. Cancer 1975; 36: 675–82
   PubMed Web of Science ®Google Scholar
• Moertel C G, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 1979; 2: 327–34
   PubMedGoogle Scholar
• Engstrom P F, Lavin P T, Folsch E, Moertel C G, Folsch E, Douglas HO. Streptozotocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumors. J Clin Oncol 1984; 2: 1255–9
   PubMed Web of Science ®Google Scholar
• Kelsen D P, Cheng E, Kemeny N, Magill G B, Yagoda A. Streptozotocin and adriamycin in the treatment of apud tumors (carcinoid, islet cell, and medullary carcinomas of the thyroid). Proc Am Assoc Cancer Res 1982; 23: 433
   Google Scholar
• Moertel C G, Rubin J, O'Connell MJ. Phase II study of cisplatin therapy in patients with metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Treat Rep 1986; 70: 1459–60
   PubMedGoogle Scholar
• Bukowski R M, Johnson K G, Peterson R F, et al. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer 1987; 60: 2891–5
   PubMed Web of Science ®Google Scholar
• Kelsen D, Fiore J, Heelan R, Cheng E, Magill G. Phase II trial of etoposide in apud tumors. Cancer Treat Rep 1987; 71: 305–7
   PubMedGoogle Scholar
• Sjoerdsma A, Lovenberg W, Engelman K, et al. Serotonin now; clinical implications of inhibiting its synthesis with parachlorophenylalanine. Ann Int Med 1970; 73: 607–29
   PubMed Web of Science ®Google Scholar
• Harris A L, Smith IE. Regression of carcinoid tumor with cyproheptadine. Br Med J 1982; 285: 475
   PubMed Web of Science ®Google Scholar
• Moertel CG. An odyssey in the land of small tumors. J Clin Oncol 1987; 5: 1503–22
   Web of Science ®Google Scholar
• Stathopoulous G P, Karvountzis G G, Yiotis J. Tamoxifen in carcinoid syndrome. N Engl Med 1981; 305–52
   Web of Science ®Google Scholar
• Myers C F, Ershler W B, Tannenbaum M A, et al. Tamoxifen and carcinoid tumor. Ann Intern Med 1982; 96: 383
   PubMed Web of Science ®Google Scholar
• Moertel C G, Engstrom P F, Schutt AJ. Tamoxifen therapy for metastatic carcinoid tumor: A negative study. Ann Int Med 1984; 100: 531–2
   PubMed Web of Science ®Google Scholar
• öberg K, Norheim I, Lind E, et al. Treatment of malignant carcinoid tumors with human leukocyte interferon: Long-term results. Cancer Treat Rep 1986; 70: 1297–1304
   PubMedGoogle Scholar
• Martin J K, Moertel C G, Adson M A, Schutt AJ. Surgical treatment of functioning metastatic carcinoid tumors. Arch Surg 1983; 118: 537–42
   PubMedGoogle Scholar
• Maton P N, Camilleri M, Griffin G, Hodgson H, Allison D J, Chadwick VS. The role of hepatic arterial embolization in the carcinoid syndrome. Br Med J 1983; 287: 932–5
   PubMed Web of Science ®Google Scholar
• Mårtensson H, Nobin A, Bengmark S, Lunderquist A, Owman T, Sandén A. Embolization of the liver in the management of metastatic carcinoid tumors. J Surg Oncol 1984; 27: 152–8
   PubMed Web of Science ®Google Scholar
• Mitty H A, Warner R RP, Newman L H, Train J S, Parnes IH. Control of carcinoid syndrome with hepatic artery embolization. Radiology 1985; 155: 623–6
   PubMed Web of Science ®Google Scholar
• Moertel C G, May G R, Martin J K, Rubin J, Schutt AJ. Sequential hepatic artery occlusion (HAO) and chemotherapy for metastatic carcinoid tumor and islet cell carcinoma (ICC). Proc Am Soc Clin Oncol 1985; 4: 80
   Google Scholar
• Frolich J C, Bloomgarden Z T, Oates J A, et al. The carcinoid flush: provocation by pentagastrin and inhibition by somatostatin. N Engl J Med 1978; 299: 1055–7
   PubMed Web of Science ®Google Scholar
• Thulin L, Samnegard H, Tydén G, Long D, Efendic S. Efficacy of somatostatin in a patient with carcinoid syndrome. Lancet 1978; 2: 43
   PubMed Web of Science ®Google Scholar
• Bauer W, Briner U, Doepfner W et al. SMS 201–995. A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133–40
   PubMed Web of Science ®Google Scholar
• Kvols L K, Moertel C G, O'Connell M J, Schutt A J, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome: evaluation of a long acting somatostatin analogue. N Engl J Med 1986; 315: 663–6
   PubMed Web of Science ®Google Scholar
• Kvols L K, Moertel C G, Schutt A J, Rubin J. Treatment of the malignant carcinoid syndrome with a long acting soma tostatin analogue (SMS 201–995): Preliminary evidence that more is not better. Proc Am Soc Clin Oncol 1987; 6: 95
   Google Scholar
• Reubi JC. A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth. Acta Endocrinol 1985; 109: 108–14
   PubMedGoogle Scholar
• Reichlin S. Somatostatin. N Engl J Med 1985; 309: 2741
   Google Scholar
• Mauer R, Reubi JC. Somatostatin receptors. JAMA 1985; 253: 2741
   PubMed Web of Science ®Google Scholar
• Reubi J C, Hacki W H, Lamberts SW. Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Met 1987; 65: 1127–34
   PubMed Web of Science ®Google Scholar
• Reubi J C, Heitz P U, Gyr K. Vasoactive intestinal peptide producing tumour contains high density of somatostatin receptors. Lancet 1987; 1: 741–2
   PubMed Web of Science ®Google Scholar
• Reubi J C, Maurer R, von Werder K, Torhorst J, Klijn J G, Lamberts SW. Somatostatin receptors in human endocrine tumors. Cancer Res 1987; 47: 551–8
   PubMed Web of Science ®Google Scholar
• Wilson D M, Hoffman AR. Reduction of pituitary size by the somatostatin analogue SMS 201–996 in a patient with an islet cell tumour secreting growth hormone releasing factor. Acta Endocrinol 1986; 113: 23–8
   PubMedGoogle Scholar
• Sullivan S J, Schonbrunn A. Characterization of somatostatin receptors which mediate inhibition of insulin secretion in Rin M5F insulinoma cells. Endocrinology 1987; 121: 544–52
   PubMed Web of Science ®Google Scholar
• Kvols L K, Buck M. Chemotherapy of metastatic carcinoid and islet cell tumors. Am J Med 1987; 82: 77–83
   PubMed Web of Science ®Google Scholar
• Mason R A, Steane PA. Carcinoid syndrome: its relevance to the anaesthetist. Anaesthesia 1976; 31: 228–42
   PubMed Web of Science ®Google Scholar
• Dery R. Theoretical and clinical consideration in anaesthesia for secreting carcinoid tumors. Can Anaesthet Soc J 1971; 18: 245–63
   PubMedGoogle Scholar
• Miller R, Patel A U, Warner R RP, Pams IH. Anaesthesia for the carcinoid syndrome: A report of nine cases. Can Anaesthet Soc J 1978; 25: 240–4
   PubMedGoogle Scholar
• Harris A L, Smith IE. Tryptophan in the treatment of carcinoid crisis. Chemother Pharmacol 1983; 10: 137–9
   PubMed Web of Science ®Google Scholar
• Marsh H M, Martin JK, Jr., Kvols L K, et al. Carcinoid crisis during anesthesia: Successful treatment with a somatostatin analogue. Anesthesiology 1987; 66: 89–91
   PubMed Web of Science ®Google Scholar
• Kvols L K, Maples W J, O'Connell MJ. Carcinoid crisis: Successful treatment and prevention with somatostatin analogue (SMS 201–995). Proc Amer Soc Clin Oncol 1987; 6: 96
   Google Scholar
• Roy R C, Carter R F, Wright PD. Somatostatin, anaesthesia, and the carcinoid syndrome. Peri-operative administration of a somatostatin analogue to suppress carcinoid tumour activity. Anaesthesia 1987; 42: 627–32
   PubMed Web of Science ®Google Scholar
• Hoeldtke R D, O'Dorisio T M, Boden G. Prevention of postprandial hypotension with somatostatin. Ann Intern Med 1985; 103: 889–90
   PubMed Web of Science ®Google Scholar
• Hoeldtke RD. Treatment of postprandial hypotension with a somatostatin analogue SMS 201–995. Am J Med 1986; 81: 83–7
   PubMed Web of Science ®Google Scholar
• Bonomi P, Hovey C, Dainauskas J R, Slayton R, Wolter J. Management of carcinoid syndrome. Med Ped Oncol 1979; 6: 77–83
   PubMedGoogle Scholar
• Kvols LK. Metastatic carcinoid tumors and the carcinoid syndrome: A selective review of chemotherapy and hormonal therapy. Am J Med 1986; 81: 49–55
   PubMed Web of Science ®Google Scholar